PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Exp Dermatol. Author manuscript; available in PMC 2010 September 1.
Published in final edited form as:
PMCID: PMC2773661
NIHMSID: NIHMS155140

Neuroendocrine activity of the melanocyte

Abstract

More than 15 years ago, we have proposed that melanocytes are sensory and regulatory cells with computing capability, which transform external and/or internal signals/energy into organized regulatory network(s) for the maintenance of the cutaneous homeostasis. This concept is substantiated by accumulating evidence that melanocytes produce classical stress neurotransmitters, neuropeptides and hormones, express corresponding receptors and these processes are modified and/or regulated by ultraviolet radiation, biological factors or stress. Examples of the above are catecholamines, serotonin, N-acetyl-serotonin, melatonin, proopiomelanocortin-derived adrenocorticotropic hormone, β-endorphin or melanocyte-stimulating hormone peptides, corticotropin releasing factor, related urocortins and corticosteroids including cortisol and corticosterone as well as their precursors. Furthermore, their production is not random, but hierarchical and follows the structures of classical neuroendocrine organizations such as hypothalamic-pituitary-adrenal axis, serotoninergic, melatoninergic and catecholaminergic systems. An example of an intrinsic but overlooked neuroendocrine activity is production and secretion of melanogenesis intermediates including L-DOPA or its derivatives that could enter circulation and act on distant sites. Such capabilities have defined melanocytes as neuroendocrine cells that not only coordinate cutaneous but also can affect a global homeostasis.

Keywords: homeostasis, hormones, melanocytes, neurotransmitters, regulatory network, sensory functions, stress

Melanocytes as sensory and regulatory cells of the epidermis: introduction into the concept

More than 15 years ago, it has been proposed for the first time that melanocytes are the sensory and regulatory cells with computing and amplifying capabilities, which detect and transform external and/or internal signals/energy into organized regulatory network(s) for the maintenance of the cutaneous homeostasis (Fig. 1) (1). Specifically, melanocytes sense the environment directly via detection and decoding of the solar or thermal energy or indirectly by responding to biological or physicochemical signals generated in the local environment in response to noxious factors. The former (detection of electromagnetic energy) represents a rapid process of which specificity depends on the chromophores or their interactions with specific receptors or metabolic pathways (2).

Figure 1
Melanocytes act as the sensory and regulatory cells of the skin with the computing capabilities. MC, melanocytes; KC, keratinocytes; LC, Langerhans cells; Ly, lymphocytes; Mast C, mast cells; MAC, macrophages; Fb, fibroblasts; EC, endothelial cells; DD, ...

This concept is in agreement with a hypothesis that melanocytes are ‘neurons of the skin’ formulated by Aaron B. Lerner (Fig. 2) (G. Moellman, personal communication). At that time it also integrated novel theories formulated at Yale University by Pawelek on the mechanism of UV regulation of melanin pigmentation (3), and the theory of the melanin epidermal unit first proposed by Fitzpatrick and Breathnach (4) and then expanded by Nordlund (5). A ground-breaking was Pawelek’s hypothesis on the transduction of electromagnetic energy of solar radiation into chemical energy during the process of ultraviolet B (UVB)-induced melanogenesis connected with an increased melanocyte-stimulating hormone (MSH) receptor activity (3,6). His laboratory (3,6) clearly demonstrated that the effects of UV on pigmentation follow the mechanisms intrinsic to the skin for the orderly, regulated reception of UV signals that are then transduced to initiate the pigmentary cascade via signals involving both melanocytes and keratinocytes. According to this model, melanotropins and their receptors played a central role in this process (3). At the same time, Nordlund has proposed that melanocytes, keratinocytes and Langerhans cells interact closely within the epidermis forming the ‘epidermal tripod unit’, a hypothesis that was updated most recently by stating that the epidermal melanin unit should be labelled the KLM unit (5). These theories (3) as well novel concepts on hormone-like bioregulatory roles for precursors and intermediates of melanogenesis L-tyrosine and L-DOPA (7), secretory functions of melanocytes and their roles in skin and hair physiology and pathology (8,9) have helped to propose that melanocytes are sensory and regulatory cells of the epidermis (1), which set-up the background for defining a melanocyte as the unique neuroendocrine cell with multiple tasks.

Figure 2
Picture of Aaron B Lerner, MD, PhD. Generously provided by Dr John Pawelek.

Melanogenic pathway as the regulator of skin homeostasis

It is unquestionable that the ability to produce melanin pigment plays a fundamental role in skin physiology and pathology and skin responsiveness to solar radiation (1012). However, a role for the intermediates of the melanogenic pathway and its final products has not been clearly established, with exception of defining the role of melanin as the protector against solar radiation (1,1013). In this context, a proposition, that precursors and intermediates of melanogenesis can act as regulators of local and systemic homeostasis (7,8), represented a mile stone in defining regulatory and neuroendocrine functions of the melanocyte (cf. 11). Specifically, it has been proposed that L-tyrosine and L-DOPA and products of their metabolic transformation can act as hormone-like or metabolic bioregulators in the skin or at systemic levels including modification of immune activity (1,7,11,1420); hormone-like, but not metabolic, properties would require expression of specific receptors for L-tyrosine and L-DOPA and their metabolites (21,22). Furthermore, we were the first to propose that melanosomes serve as unique organelle/messengers, which regulate skin functions including its protective, bioregulatory and sensory capability, because of intrinsic melanin and melanosomal properties and the bioregulatory functions of melanogenic pathway (1,8). Part of this model has latter been adopted by other investigators (12,23,24).

Neuroendocrine functions of the melanocyte

Since then, this concept has been substantiated by significant experimental evidence showing that melanocytes produce classical stress neurotransmitters, neuropeptides and hormones, and that this production is stimulated by ultraviolet radiation, biological factors and other agents that act within the skin neuroendocrine system (reviewed in (14,2529). Specifically, melanocytes produce corticotropin releasing factor (CRF) and related urocortin, and express corresponding functionally active CRF receptors types 1 and 2 (CRF1 and CRF2) (2830). Signal transduction through the CRF receptors is coupled to different second messengers including cAMP, IP3 and Ca+2 to most optimally regulate the phenotypic outcome such as melanogenesis, dendrite proliferation and regulation of cell proliferation (29,31,32) or NFκB activity (33) in a process that includes alternative splicing (29,34). Furthermore, melanocytes express proopiomelanocortin (POMC) that is processed to adrenocorticotropic hormone (ACTH), α-MSH and β-endorphin [(30,35,36) and reviewed in (11,26)], express MC1-R (37,38), MC2-R (39), MC-4 (40) and opioid receptors (41) and have corticosteroidogenic potential (4244). Most recent data (40) have also confirmed our initial detection of cutaneous production of β-MSH by immunocytochemistry (45,46). Synthesis of steroid hormones in melanocytes can start from the cleavage of the side chain of cholesterol (42). Most importantly, the melanocyte CRF production and expression of CRF1 are regulated by UVB (29,34,47,48), CRF stimulates production of POMC with production of ACTH and α-MSH (43,49) and UVB-induced POMC and ACTH expression is dependent on the CRF production and CRF1 signal transduction (47). Thus, an evidence has been provided for the original hypothesis (50) that the production of the above molecules in pigment cells is hierarchical, and follows the algorithm of a classical neuroendocrine axis—hypothalamic-pituitary-adrenal axis (HPA) (25,29,43,51). This raised important questions on the evolution of the stress response system, which may have originated in the integument as well as on possible systemic implications of this process (14,26, 5255).

Additional examples of melanocyte neuroendocrine activity are its ability to produce and secrete L-DOPA [a hormone-like bioregulator and a potential neurotransmitter (7,11,21)], its metabolic products (11), as well as production of catecholamines (56). The latter capability is significant as melanocytes express phenylalanine hydroxylase, tyrosine hydroxylase, express functional adrenergic receptors as well as have a capability for de novo synthesis/recycling and regulation of the pterin (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (6BH4) (5659). Importantly, we have demonstrated recently that normal and malignant melanocytes have the capability to transform L-tryptophan to serotonin, N-acetylserotonin and melatonin with its further metabolism (6064). The serotoninergic/melatoninergic system is functional within the pigmentary system and melanocytes express serotonin and melatonin receptors (11,65,66). Lastly melanocytes can express elements of the hypothalamic-pituitary-thyroid axis (67) and elements of the cholinergic system (56).

Concluding remarks

The above capabilities clearly demonstrated that melanocytes could efficiently regulate local and perhaps systemic homeostasis. The latter may include direct release into circulation of the melanocyte signalling molecules (endocrine effect), or neurotransmitter-like effects by activation of specific receptors on cutaneous sensory nerve endings or by changing physicochemical environment surrounding such nerves (1,14,53,55). Accordingly, the cutaneous sensory nerves will signal the brain on changes in the epidermal environment or will relay to neuronal reflexes without brain involvement (1,14,55). These capabilities represent a dawn for the novel role of melanocytes, as neuroendocrine cells that translate environmental information into both local and systemic effects (1,14). In this context, when stressed, the skin pigmentary system can generate signals to produce rapid (neural) or slow (humoral) responses at the local or systemic levels (1,7,11). These responses are addressed at counteracting the environmental insults, and/or modulating optimally the homeostatic adaptation mechanisms. Thus, the skin melanocytic system may act as a sensor for external or internal disturbances to generate humoral or neural signals sent to local or distant coordinating centres (Fig. 1) as originally proposed by us (1,7,11,14).

Acknowledgments

This manuscript is based on the Aaron B. Lerner/PASPCR Special Lecture presented by Dr Slominski on 12 May, 2008 during joined XXth IPCC and Vth IMRS meetings in Sapporo, Japan, 12 May, 2008, which has been sponsored by Johnson & Johnson Consumer Companies. The contribution of Drs J. Pawelek, Dr R. Paus and Dr D. Tobin to the development of the above concept is acknowledged. This publication was made possible by Johnson & Johnson Consumer Companies and in part by Grants number AR052190 and AR047079 from the NIH/NIAMS.

References

1. Slominski A, Paus R, Schanderdorf D. Melanocytes as sensory and regulatory cells in the epidermis. J Theor Biol. 1993;164:103–120. [PubMed]
2. Slominski A, Pawelek J. Animals under the sun: effects of ultraviolet radiation on mammalian skin. Clin Dermatol. 1998;16:503–515. [PubMed]
3. Pawelek JM, Chakraborty AK, Osber MP, et al. Molecular cascades in UV-induced melanogenesis: a central role for melanotropins? Pigment Cell Res. 1992;5:348–356. [PubMed]
4. Fitzpatrick TB, Breathnach AS. Das epidermale melanin-einheit-system. Dermatol Wochenschr. 1963;147:481–489. [PubMed]
5. Nordlund JJ. The melanocyte and the epidermal melanin unit: an expanded concept. Dermatol Clin. 2007;25:271–281. vii. [PubMed]
6. Bolognia J, Murray M, Pawelek J. UVB-induced melanogenesis may be mediated through the MSH-receptor system. J Invest Dermatol. 1989;92:651–656. [PubMed]
7. Slominski A, Paus R. Are L-tyrosine and L-dopa hormone-like bioregulators? J Theor Biol. 1990;143:123–138. [PubMed]
8. Slominski A, Paus R. Melanogenesis is coupled to murine anagen: toward new concepts for the role of melanocytes and the regulation of melanogenesis in hair growth. J Invest Dermatol. 1993;101:90S–97S. [PubMed]
9. Slominski A, Paus R, Wortsman J. On the potential role of proopiomelanocortin in skin physiology and pathology. Mol Cell Endocrinol. 1993;93:C1–C6. [PubMed]
10. Nordlund JJ, Boissy RE, Hearing VJ, King RA, Oetting WS, Ortonne J-P. The Pigmentary System: Physiology and Pathophysiology. Malden: Blackwell Publishing; 2006.
11. Slominski A, Tobin DJ, Shibahara S, Wortsman J. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev. 2004;84:1155–1228. [PubMed]
12. Wood JM, Jimbow K, Boissy RE, et al. What’s the use of generating melanin? Exp Dermatol. 1999;8:153–164. [PubMed]
13. Hoogduijn MJ, Cemeli E, Ross K, Anderson D, Thody AJ, Wood JM. Melanin protects melanocytes and keratinocytes against H2O2-induced DNA strand breaks through its ability to bind Ca2+ Exp Cell Res. 2004;294:60–67. [PubMed]
14. Slominski A, Wortsman J. Neuroendocrinology of the skin. Endocrine Rev. 2000;21:457–487. [PubMed]
15. Slominski A, Goodman-Snitkoff GG. Dopa inhibits induced proliferative activity of murine and human lymphocytes. Anticancer Res. 1992;12:753–756. [PubMed]
16. Slominski A, Paus R, Mihm MC. Inhibition of melanogenesis as an adjuvant strategy in the treatment of melanotic melanomas: selective review and hypothesis. Anticancer Res. 1998;18:3709–3715. [PubMed]
17. Slominski A, Friedrich T. L-dopa inhibits in vitro phosphorylation of melanoma glycoproteins. Pigment Cell Res. 1992;5:396–399. [PubMed]
18. Slominski A, Moellman G, Kuklinska E, Bomirski A, Pawelek J. Positive regulation of melanin pigmentation by two key substrates of the melanogenic pathway: L-tyrosine and L-dopa. J Cell Sci. 1988;89:287–296. [PubMed]
19. Slominski A, Moellmann G, Kuklinska E. L-tyrosine, L-dopa and tyrosinase as positive regulators of the subcellular apparatus of melanogenesis in Bomirski Ab amelanotic melanoma. Pigment Cell Res. 1989;2:109–116. [PubMed]
20. Slominski A, Jastreboff P, Pawelek J. L-tyrosine stimulates induction of tyrosinase activity by MSH and reduces cooperative interactions between MSH receptors in hamster melanoma cells. Biosci Rep. 1989;9:579–586. [PubMed]
21. Slominski A, Paus R. Towards defining receptors for L-tyrosine and L-dopa. Mol Cell Endocrinol. 1994;99:C7–C11. [PubMed]
22. Slominski A, Pruski D. L-dopa binding sites in rodent melanoma cells. Biochim Biophys Acta. 1992;1139:324–328. [PubMed]
23. Costin GE, Hearing VJ. Human skin pigmentation: melanocytes modulate skin color in response to stress. FASEB J. 2007;21:976–994. [PubMed]
24. Hearing VJ. Biogenesis of pigment granules: a sensitive way to regulate melanocyte function. J Dermatol Sci. 2005;37:3–14. [PubMed]
25. Slominski A, Wortsman J, Tuckey RC, Paus R. Differential expression of HPA axis homolog in the skin. Mol Cell Endocrinol. 2007;266:143–149. [PMC free article] [PubMed]
26. Slominski A, Wortsman J, Luger T, Paus R, Solomon S. Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol Rev. 2000;80:979–1020. [PubMed]
27. Schallreuter K, Slominski A, Pawelek JM, Jimbow K, Gilchrest BA. What controls melanogenesis? Exp Dermatol. 1998;7:143–150. [PubMed]
28. Slominski A, Wortsman J, Pisarchik A, et al. Cutaneous expression of corticotropin releasing hormone (CRH), urocortin, and CRH receptors. FASEB J. 2001;15:1678–1693. [PubMed]
29. Slominski A, Zbytek B, Zmijewski M, et al. Corticotropin releasing hormone and the skin. Front Biosci. 2006;11:2230–2248. [PMC free article] [PubMed]
30. Slominski A, Ermak G, Hwang J, Chakraborty A, Mazurkiewicz JE, Mihm M. Proopiomelanocortin, corticotropin releasing hormone and corticotropin releasing hormone receptor genes are expressed in human skin. FEBS Lett. 1995;374:113–116. [PubMed]
31. Slominski A, Zbytek B, Pisarchik A, Slominski RM, Wortsman J. CRH functions as a growth factor/cytokine in the skin. J Cell Physiol. 2006;206:780–791. [PMC free article] [PubMed]
32. Kauser S, Slominski A, Wei ET, Tobin DJ. Modulation of the human hair follicle pigmentary unit by corticotropin-releasing hormone and urocortin peptides. FASEB J. 2006;20:882–895. [PMC free article] [PubMed]
33. Zbytek B, Pfeffer LM, Slominski AT. CRH inhibits NF-kappaB signaling in human melanocytes. Peptides. 2006;27:3276–3283. [PMC free article] [PubMed]
34. Pisarchik A, Slominski AT. Alternative splicing of CRH-R1 receptors in human and mouse skin: identification of new variants and their differential expression. FASEB J. 2001;15:2754–2756. [PubMed]
35. Slominski A. Identification of beta-endorphin, alpha-MSH and ACTH peptides in cultured human melanocytes, melanoma and squamous cell carcinoma cells by RP-HPLC. Exp Dermatol. 1998;7:213–216. [PubMed]
36. Slominski A. POMC gene expression in hamster and mouse melanoma cells. FEBS Lett. 1991;291:165–168. [PubMed]
37. Abdel-Malek Z, Scott MC, Suzuki I, et al. The melanocortin-1 receptor is a key regulator of human cutaneous pigmentation. Pigment Cell Res. 2000;13(Suppl 8):156–162. [PubMed]
38. Bohm M, Luger TA, Tobin DJ, Garcia-Borron JC. Melanocortin receptor ligands: new horizons for skin biology and clinical dermatology. J Invest Dermatol. 2006;126:1966–1975. [PubMed]
39. Slominski A, Ermak G, Mihm M. ACTH receptor, CYP11A1, CYP17 and CYP21A2 genes are expressed in skin. J Clin Endocrinol Metab. 1996;81:2746–2749. [PubMed]
40. Spencer JD, Schallreuter KU. Regulation of pigmentation in human epidermal melanocytes by functional high affinity {beta}-MSH/MC4-R signalling. Endocrinology. 2009;150:1250–1258. [PubMed]
41. Kauser S, Schallreuter KU, Thody AJ, Gummer C, Tobin DJ. Regulation of human epidermal melanocyte biology by beta-endorphin. J Invest Dermatol. 2003;120:1073–1080. [PubMed]
42. Slominski A, Zjawiony J, Wortsman J, et al. A novel pathway for sequential transformation of 7-dehydrocholesterol and expression of the P450scc system in mammalian skin. Eur J Biochem. 2004;271:4178–4188. [PMC free article] [PubMed]
43. Slominski A, Zbytek B, Szczesniewski A, et al. CRH stimulation of corticosteroids production in melanocytes is mediated by ACTH. Am J Physiol Endocrinol Metab. 2005;288:E701–E706. [PubMed]
44. Slominski A, Gomez-Sanchez CE, Foecking MF, Wortsman J. Metabolism of progesterone to DOC, corticosterone and 18OHDOC in cultured human melanoma cells. FEBS Lett. 1999;455:364–366. [PubMed]
45. Slominski A, Wortsman J, Mazurkiewicz JE, et al. Detection of proopiomelanocortin-derived antigens in normal and pathologic human skin. J Lab Clin Med. 1993;122:658–666. [PubMed]
46. Slominski A, Heasley D, Mazurkiewicz JE, Ermak G, Baker J, Carlson JA. Expression of proopiomelanocortin (POMC)-derived melanocyte-stimulating hormone (MSH) and adrenocorticotropic hormone (ACTH) peptides in skin of basal cell carcinoma patients. Hum Pathol. 1999;30:208–215. [PubMed]
47. Zbytek B, Wortsman J, Slominski A. Characterization of a ultraviolet B-induced corticotropin-releasing hormone-proopiomelanocortin system in human melanocytes. Mol Endocrinol. 2006;20:2539–2547. [PMC free article] [PubMed]
48. Slominski A, Baker J, Ermak G, Chakraborty A, Pawelek J. Ultraviolet B stimulates production of corticotropin releasing factor (CRF) by human melanocytes. FEBS Lett. 1996;399:175–176. [PubMed]
49. Rousseau K, Kauser S, Pritchard LE, et al. Proopiomelanocortin (POMC), the ACTH/melanocortin precursor, is secreted by human epidermal keratinocytes and melanocytes and stimulates melanogenesis. FASEB J. 2007;21:1844–1856. [PMC free article] [PubMed]
50. Slominski A, Mihm M. Potential mechanism of skin response to stress. Int J Dermatol. 1996;35:849–851. [PubMed]
51. Zmijewski MA, Sharma RK, Slominski AT. Expression of molecular equivalent of hypothalamic-pituitary-adrenal axis in adult retinal pigment epithelium. J Endocrinol. 2007;193:157–169. [PubMed]
52. Slominski A. A nervous breakdown in the skin: stress and the epidermal barrier. J Clin Invest. 2007;117:3166–3169. [PMC free article] [PubMed]
53. Slominski A, Wortsman J, Paus R, Tobin D, Elias P, Feingold K. Skin as an endocrine organ: implications for its function. Drug Discov Today: Dis Mech. 2008;5:e137–e144. [PMC free article] [PubMed]
54. Ito N, Ito T, Kromminga A, et al. Human hair follicles display a functional equivalent of the hypothalamic-pituitary-adrenal axis and synthesize cortisol. FASEB J. 2005;19:1332–1334. [PubMed]
55. Slominski A. Neuroendocrine system of the skin. Dermatology. 2005;211:199–208. [PMC free article] [PubMed]
56. Grando SA, Pittelkow MR, Schallreuter KU. Adrenergic and cholinergic control in the biology of epidermis: physiological and clinical significance. J Invest Dermatol. 2006;126:1948–1965. [PubMed]
57. Schallreuter KU, Kothari S, Chavan B, Spencer JD. Regulation of melanogenesis – controversies and new concepts. Exp Dermatol. 2008;17:395–404. [PubMed]
58. Marles LK, Peters EM, Tobin DJ, Hibberts NA, Schallreuter KU. Tyrosine hydroxylase isoenzyme I is present in human melanosomes: a possible novel function in pigmentation. Exp Dermatol. 2003;12:61–70. [PubMed]
59. Schallreuter KU. A review of recent advances on the regulation of pigmentation in the human epidermis. Cell Mol Biol (Noisy-le-grand) 1999;45:943–949. [PubMed]
60. Slominski A, Semak I, Pisarchik A, Sweatman T, Szczesniewski A, Worstman J. Conversion of L-tryptophan to serotonin and melatonin in melanoma cells. FEBS Lett. 2002;511:102–106. [PubMed]
61. Slominski A, Pisarchik A, Semak I, et al. Serotoninergic and melatoninergic systems are fully expressed in human skin. FASEB J. 2002;16:896–898. [PubMed]
62. Slominski A, Wortsman J, Tobin DJ. The cutaneous serotoninergic/melatoninergic system: securing a place under the sun. FASEB J. 2005;19:176–194. [PubMed]
63. Slominski A, Tobin DJ, Zmijewski MA, Wortsman J, Paus R. Melatonin in the skin: synthesis, metabolism and functions. Trends Endocrinol Metab. 2008;19:17–24. [PubMed]
64. Slominski A, Pisarchik A, Johansson O, et al. Tryptophan hydroxylase (TPH) expression in human skin cells. Biochim Biophys Acta. 2003;1639:80–86. [PubMed]
65. Slominski A, Pisarchik A, Zbytek B, Tobin DJ, Kauser S, Wortsman J. Functional activity of serotoninergic and melatoninergic systems expressed in the skin. J Cell Physiol. 2003;196:144–153. [PubMed]
66. Slominski A, Fischer TW, Zmijewski MA, et al. On the role of melatonin in skin physiology and pathology. Endocrine. 2005;27:137–148. [PMC free article] [PubMed]
67. Slominski A, Wortsman J, Kohn L, et al. Expression of hypothalamic-pituitary-thyroid axis related genes in the human skin. J Invest Dermatol. 2002;119:1449–1455. [PMC free article] [PubMed]